Information Provided By: 
Fly News Breaks for February 29, 2016
OREX
Feb 29, 2016 | 08:38 EDT
As noted earlier, RBC Capital downgraded Orexigen to Sector Perform from Outperform. The firm says that it expects the company's obesity drug, Contrave, to have "a dififuclt 2016," due to what it sees as the smaller than expected size of the obesity pharmacotherapy market. Target to $1 from $5.
News For OREX From the Last 2 Days
There are no results for your query OREX
